Cargando…
Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials
BACKGROUND: NVX-CoV2373 (Nuvaxovid™ or the Novavax COVID-19 Vaccine, Adjuvanted), the first protein-based COVID-19 vaccine, received emergency use authorization (EUA) as a primary series/booster and is available globally. NVX-CoV2373 primary series demonstrated efficacy rates of 89.7–90.4 % and an a...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors. Published by Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169578/ https://www.ncbi.nlm.nih.gov/pubmed/37211453 http://dx.doi.org/10.1016/j.vaccine.2023.05.016 |